1Hernandez-hernandez R, Velasco M, Armas-herna-ndez M J,et al. Angiotensin Ⅱ receptor antagonists in arterial hypertension[J]. J hum hypertens, 2000, 14 (suppl 1) : S69-S72.
2Neutel J M, Bedigian M P. Efficacy of valsartan in patients aged≥ 65 years with systolic hypertension[J]. Clin Ther, 2000,22(8) :961-969.
3Crozier I, Ikram H, Awan N, et al. Losartan in heart failure:Hemodynamic effects and tolerability[J]. Circulation, 1995,91(3) :691-697.
4Gottlieb S S, Dickstein K, Fleck E, et al. Hemodynamic and neurohormonal effect of the angiotensin Ⅱ antagonist losartan in patients with congestiv heart failure[J]. Circulation, 1993,88(part 1) : 1602-1609.
5Horiuchi M, Akishita M,Dzau V J, et al. Recent progress in angiotensin Ⅱ type 2 receptor research in the cardiovascular system[J] . Hypertension, 1999,33 (2): 613-621.
6Robert V, Silvestre J S, Charlemagne D, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rat[J].Hypertension, 1995,26(6 part 1 ): 971-978.
同被引文献3
1Hernndez-hernndez R, Velasco M, Armashernondez M J, et al. Angiotensin receptor antagonists in arterial hypertension[J]. J Hum Hypertens, 2000,14 (Suppl 1) :69-72.
2Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged ≥65 years with systolic hypertension [J]. Clin Ther,2000,22 ( 8 ) :961-969.
